TABLE 2.
Characteristics of Studies That Assessed Obesity in Pediatric ALL Survivors Off Treatment 5 to 9 Years
| Author, Year (Location) | Study Design | Type of Controla | Survivors, n /(Control) | Years at Dx | Age at Studyb | Years Since Dxb | % CRT | Major Findingsc | By Genderd | By CRTd |
|---|---|---|---|---|---|---|---|---|---|---|
| BMI z score | ||||||||||
| Birkebaek et al 1998 (Denmark) | L | Normative (French) | 33 | 1973–1984 | 16.4 | 12.1 | 66.7 | 0.6 | N/A | CRT+: 0.6, CRT –: 0.6 |
| Craig et al 1999 (UK) | L | Normative (British) | 213 | 1971–1994 | 17.0 | 13.8 | 100 | 0.4 | M: 0.2, F: 0.6 | N/A |
| Mayer et al 2000 (Germany) | L | Normative (British) | 39 | 1981–1990 | 14.2 | 8.9 | 64.1 | 1.5 | N/A | CRT+: 1.9, CRT–: 0.9 |
| Sklar et al 2000 (US) | L | Normative (NHANES II) | 126 | 1969–1982 | 18.3 | 11.9 | 70.0 | 0.5 | M: 0.5, F: 0.5 | CRT+: 0.7, CRT–: 0.04 |
| van der Sluis et al 2000 (Netherlands) | CS | Normative (British) | 23 | 1984–1988 | 17.2 | 11.8 | 0 | 0.5 | M: 0.6, F: 0.5 | N/A |
| Warner et al 2002 (UK) | CS | Normative (British) and external (sibling) | 35/31 | 1979–1990 | 12.1 | 9.1 | 100 | 1.3/0.7 | M: 0.3, F: 1.6 | N/A |
| Papadia et al 2006 (Brazil) | CS | Normative (British) and external | 27/17 | 2002–2003 | 14.0 | 8.5 | 100 | −0.03/–0.5 | N/A | N/A |
| Chow et al 2007 (US) | L | Normative (CDC) | 24 | 1993–2003 | 11.9 | 10.5 | 19.4 | 0.8 | N/A | None |
| Karaman et al 2010 (Turkey) | CS | Normative (Turkey) and external | 93/50 | 1975–2002 | 15.6 | 12.7 | 79.6 | 1.2/0.7* | None | None |
| Kohler et al 2011 (UK) | CS | Normative (British) and external | 54/51 | MRC UKALL XI ALL 97/99/2003 | 14.0 | 8.3 | 0 | 0.5/0.3 | M: 0.3, F: 0.7* | N/A |
| Aldhafiri et al 2012 (Saudi Arabia) | CS | Normative (WHO) | 56 | 1994–2009 | 13.4 | 9.1 | 0 | −0.04 | M: –0.2, F: 0.2 | N/A |
| BMI percentile | ||||||||||
| Karaman et al 2010 (Turkey) | CS | Normative (Turkey) and external | 93/50 | 1975–2002 | 15.6 | 12.7 | 79.6 | 71.7/62.3 | None | None |
| Love et al 2011 (Canada) | L | Normative (CDC) | 102 | N/A | 14.3 | 9.5 | 8.0 | 66.5 | None | N/A |
| Skoczen et al 2011 (Poland) | L | Normative (British) | 82 | 1985–2005 | 13.2 | 7.8 | 38.0 | 65.5 | N/A | N/A |
| Ratio of BMI/mean BMI | ||||||||||
| Schell et al 1992 (US) | L | Normative (NCHS) | 91 | 1967–1975 | 18.0 | 12.3 | 100 | 1.09 | N/A | N/A |
| BMI | ||||||||||
| Karaman et al 2010 (Turkey) | CS | Normative (Turkey) and external | 93/50 | 1975–2002 | 15.6 | 10.2 | 79.6 | 21.7/20.3* | M: 21.8, F: 21.5 | CRT+: 21.8, CRT–: 20.9 |
| % fat | ||||||||||
| Warner et al 2002 (UK) | CS | Normative (British) and external (sibling) | 35/32 | 1979–1990 | 12.1 | 9.1 | 100 | 28.7/20.6 | M: 21.5/17.6, F: 33.5/24.5 | N/A |
| % OW/OB | ||||||||||
| Zee et al 1986 (US) | L | Normative (NCHS) | 253 | 1966–1984 | N/A | 7.5 | 100 | OB: 8% | N/A | N/A |
| Schell et al 1992 (US) | L | Normative (NCHS) | 91 | 1967–1975 | 18.0 | 12.3 | 100 | OW/OB: 38% | N/A | N/A |
| Didi et al 1995 (UK) | L | Normative (British) | 114 | 1971–1987 | 16.2 | 10.2 | 100 | OB: 46% | M: 45%, F: 47% | N/A |
| Davies et al 1995 (UK) | L | Normative (French) | 114 | N/A | N/A | N/A | 100 | OW/OB: 47% | M: 45%, F: 48% | N/A |
| Sklar et al 2000 (US) | L | Normative (NHANES II) | 126 | 1969–1982 | 18.3 | 11.9 | 70.0 | OW/OB: 30% | None | CRT+: 39%, CRT–: 11% |
| Mayer et al 2000 (Germany) | L | Normative (British) | 39 | 1981–1990 | 14.2 | 8.9 | 64.1 | OW/OB: 38% | M: 39%, F: 38% | CRT+: 48%, CRT–: 21% |
| Nathan et al 2006 (Canada) | CS | Normative (CDC) | 83 | 1986–1999 | 14.7 | 9.7 | 23.7 | OW: 24%, OB: 14% | M: 41%, F: 34% | None |
| Razzouk et al 2007 (US) | L | Normative (CDC and NHANES II) | 248 | 1979–1984 | 18.4 | 11.9 | 58.1 | OW: 16%, OB: 21% | Yes | None |
| Trimis et al 2007 (Greece) | CS | Normative (Greek) | 80 | 1991–2002 | 13.9 | 8.8 | 22.5 | OW: 44%, OB: 25% | N/A | CRT+: 55%, CRT–: 40% |
| Asner et al 2008 (Switzerland) | L | Normative (Switzerland) | 54 | 1990–2000 | N/A | 8.5 | 0 | OW: 30%, OB: 18% | None | N/A |
| Tylavsky et al 2010 (US) | CS | Normative (CDC) | 164 | 1984–1997 | 19.6 | 9.7 | N/A | OW: 26%, OB: 31% | N/A | Yes |
| Love et al 2011 (Canada) | L | Normative (CDC) | 102 | N/A | 14.3 | 9.5 | 8 | OW/OB: 35% | M: 21%, F: 47%* | N/A |
| Aldhafiri et al 2012 (Saudi Arabia) | CS | Normative (WHO/CDC) | 56 | 1994–2009 | 13.4 | 9.1 | 0 | OW: 18%, OB: 11% | N/A | N/A |
| Skoczen et al 2011 (Poland) | L | Normative (British) | 82 | 1985–2005 | 13.2 | 7.8 | 38.0 | OW/OB: 31% | N/A | CRT+:23%, CRT–: 35% |
CRT+, survivors treated with CRT; CRT–, survivors treated with no CRT; CS, cross-sectional; Dx, diagnosis; F, female survivors; L, longitudinal; M, male survivors; MRC, Medical Research Council; N/A, values were not presented for subgroups; NCHS, National Center for Health Statistics; OB, obesity; OW, overweight; WHO, World Health Organization.
Normative controls are reference populations used to calculate BMI z score or percentile. External controls are usually age- and/or gender-matched healthy unrelated individuals unless sibling controls are indicated.
Age at study and year since Dx are the mean or median as reported or estimated based on the reported age at diagnosis and duration of follow-up (the mean duration of treatment was estimated to be 2.5 y if not indicated by the study).
Weighted average was calculated if values were provided separately for subgroups (eg, M and F, survivors treated with CRT and without CRT).
None: the study indicated no difference by subgroups, but the actual values were not reported for subgroups. Yes: the study indicated a difference by subgroups, but the actual values were not reported for subgroups.
The study reported the subgroup difference was statistically different (P < .05).